Cybin Revenue and Competitors

Toronto, ON CAN

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Cybin's estimated annual revenue is currently $11.3M per year.(i)
  • Cybin's estimated revenue per employee is $155,000

Employee Data

  • Cybin has 73 Employees.(i)
  • Cybin grew their employee count by 7% last year.

Cybin's People

NameTitleEmail/Phone
1
Co-founderReveal Email/Phone
2
CEOReveal Email/Phone
3
Head Legal EuropeReveal Email/Phone
4
Director, Clinical DevelopmentReveal Email/Phone
5
Sr Director, Clinical ProgramsReveal Email/Phone
6
Director Financial Planning and AnalysisReveal Email/Phone
7
Cofounder & DirectorReveal Email/Phone
8
Chief Operating OfficerReveal Email/Phone
9
Chief Medical OfficerReveal Email/Phone
10
Associate DirectorReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$16.9M10911%N/AN/A
#2
$6040M286095%$1.5B$3.3B
#3
$7.5M9053%N/AN/A
Add Company

What Is Cybin?

Cybin is a biotech company advancing psychedelic pharmaceutical treatments for various psychiatric and neurological conditions.

keywords:N/A

N/A

Total Funding

73

Number of Employees

$11.3M

Revenue (est)

7%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Cybin News

2022-04-17 - Cybin to Participate in the KCSA Psychedelics Virtual Investor ...

Cybin is a leading ethical biopharmaceutical company, working with a network of world-class partners and internationally recognized scientists,...

2022-04-17 - Cybin Partners with Clinilabs Drug Development Corporation ...

Cybin Partners with Clinilabs Drug Development Corporation for Phase 1/2a Trial Evaluating CYB003 for the Treatment of Major Depressive Disorder.

2022-04-13 - Cybin Announces Positive CYB004 Data Demonstrating ...

Cybin Announces Positive CYB004 Data Demonstrating Significant Advantages Over Intravenous and Inhaled DMT. - Delivery of CYB004 via inhalation...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$17.7M73-35%N/A
#2
$13.8M737%N/A
#3
$9.5M73N/AN/A
#4
$9.9M7311%N/A
#5
$16.4M73-34%N/A